Search arXiv⌕ Search
Home/Archive/arXiv

arXiv · q-bio/0504011

Design of HIV-1-PR inhibitors which do not create resistance: blocking the folding of single monomers

R. A. Broglia·G. Tiana·L. Sutto·D. Provasi·F. Simona
View original source ↗Read source document ↗Export metadata ↓

Abstract

One of the main problems of drug design is that of optimizing the drug--target interaction. In the case in which the target is a viral protein displaying a high mutation rate, a second problem arises, namely the eventual development of resistance. We wish to suggest a scheme for the design of non--conventional drugs which do not face any of these problems and apply it to the case of HIV--1 protease. It is based on the knowledge that the folding of single--domain proteins, like e.g. each of the monomers forming the HIV--1--PR homodimer, is controlled by local elementary structures (LES), stabilized by local contacts among hydrophobic, strongly interacting and highly conserved amino acids which play a central role in the folding process. Because LES have evolved over myriads of generations to recognize and strongly interact with each other so as to make the protein fold fast as well as to avoid aggregation with other proteins, highly specific (and thus little toxic) as well as effective folding--inhibitor drugs suggest themselves: short peptides (or eventually their mimetic molecules), displaying the same amino acid sequence of that of LES (p--LES). Aside from being specific and efficient, these inhibitors are expected not to induce resistance: in fact, mutations which successfully avoid their action imply the destabilization of one or more LES and thus should lead to protein denaturation. Making use of Monte Carlo simulations within the framework of a simple although not oversimplified model, which is able to reproduce the main thermodynamic as well as dynamic properties of monoglobular proteins, we first identify the LES of the HIV--1--PR and then show that the corresponding p--LES peptides act as effective inhibitors of the folding of the protease which do not create resistance.

Explore related subjects

q-bio.BM

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R. A. Broglia, G. Tiana, L. Sutto, D. Provasi, F. Simona. 2005-04-07. Design of HIV-1-PR inhibitors which do not create resistance: blocking the folding of single monomers. https://arxiv.org/abs/q-bio/0504011

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related papers

arXiv2026

PocketVE: Stable and Property-Guided Structure-Based Drug Design with Variance-Exploding Diffusion

Protein-conditioned 3D molecule generation is a central challenge in structure-based drug design, requiring a balance between pocket compatibility, molecular properties, and physical geometry. We propose \textbf{PocketVE}, a protein-pocket-conditioned variance-exploding (VE) diffusion framework that couples stable coordinate denoising with inference-time property guidance. Specifically, PocketVE combines an EDM-style training and sampling setup for 3D denoising, classifier-free guidance for multi-property steering without external property classifiers, and adaptive protein perturbation as a training-time pocket regularizer. Evaluated on CrossDocked2020 under the GenBench3D protocol, PocketVE improves Valid$_{3\text{D}}$ from 58.6 to 80.6 and reduces strain energy from 457.4 to 127.9 relative to its TAGMol architectural baseline, while retaining competitive docking and molecular-property scores under moderate guidance. A guidance-scale study shows that moderate guidance gives a favorable balance between target-related objectives and geometric quality, whereas stronger guidance can degrade geometry and distributional fidelity. Pocket-permutation and PoseCheck diagnostics further support pocket-specific spatial compatibility with reduced steric conflicts. Overall, the results suggest that geometric stability and inference-time property guidance should be considered as coupled design objectives.

q-bio.BM↗
arXiv2026

In Vivo Length Distributions as Mechanistic Fingerprints of Pathological Protein Aggregation

Modern imaging techniques can resolve individual pathological protein aggregates in postmortem human samples, providing detailed measurements of aggregate size distributions that are inaccessible with conventional bulk approaches. These distributions represent mechanistic fingerprints of the microscopic processes that generated the observed pathology, but extracting this mechanistic information requires a quantitative theoretical framework. Here, we develop the mathematical tools needed to interpret aggregate length distributions in living systems, where aggregate growth competes with active removal. We show that, across a class of models, the length distribution of sufficiently large aggregates approaches a geometric decay. Crucially, the decay rate is determined by the balance between aggregate elongation and removal, providing a direct quantitative readout of these competing processes from a single time point measurement. This enables mechanistic comparisons between healthy and diseased human samples without requiring longitudinal measurements of aggregate dynamics. We further analyse how additional aggregation and removal processes modify the observed length distributions. Together, these results establish the mathematical foundations and tools to use aggregate length distributions as an experimentally accessible route for inferring microscopic aggregation dynamics directly from human tissue.

q-bio.BM↗
arXiv2026

Decoding enzyme-substrate interaction topology reveals principles underlying catalytic efficiency and mutational outcomes

The enzyme turnover number (kcat) defines catalytic efficiency and constrains quantitative models of metabolism, yet the molecular determinants governing kcat and its response to mutation remain poorly understood. Measurements are sparse and labor-intensive, and most computational approaches provide numerical predictions without explaining how enzyme-substrate interactions shape catalytic outcomes. A central challenge is therefore to identify the topological principles that determine where mutations act and how their functional outcomes are encoded within the enzyme-substrate interaction network. Here, we show that catalytic efficiency and mutational effects can be interpreted through enzyme-substrate interaction topology. We developed Interkcat, an interpretable bidirectional cross-attention framework that captures reciprocal coordination between protein residues and substrate atoms. Optimized on a unified benchmark, Interkcat achieves state-of-the-art predictive performance (R2 = 0.701). From its learned representations, we derive an Interaction Topology Score (ITS) that identifies sequence regions statistically enriched for mutation-sensitive sites without explicit structural inputs. We further demonstrate that higher-order topological features distinguish opposing mutational outcomes: lethal mutations disrupt coordinated networks, whereas activity-preserving or enhancing mutations retain sparse, globally organized coupling. These findings establish interaction topology as a unifying principle linking enzyme sequence, catalytic efficiency, and evolutionary perturbation.

q-bio.BM↗